Autolus Therapeutics AUTL 深 沪
等待开盘 03-30 09:30:00 美东时间
1.21
-0.080
-6.20%
华盛通- 最 高1.2699
- 今 开1.21
- 成交量 484.78万股
- 最 低 1.175
- 昨 收 1.29
- 总市值 3.22亿
- 52周最高 2.70
- 市盈率 静 --
- 换手率 1.82%
- 52周最低 1.105
- 委 比 -73.18%
- 总股本 2.66亿
- 历史最高 53.24
- 量 比 2.33
- 振 幅 7.36%
- 历史最低 1.105
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
今天 11:49
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
03-28 00:21
Autolus Highlights AUCATZYL Launch and Pipeline Advancements
Autolus Therapeutics ( ($AUTL) ) has provided an update. Autolus Therapeutics r...
03-27 21:11
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Autolus Therapeutics Q4 EPS $(0.34) Misses $(0.24) Estimate, Sales $24.289M Miss $24.481M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.24) by 41.08 percent. This is a 277.78 percent decrease over losses of $(0.09) per
03-27 19:01
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus Therapeutics will release its 2025 Q4 and full-year financial results on March 27, 2026, before U.S. markets open. Management will host a conference call at 8:30am EDT / 12:30pm GMT to discuss results and provide a business update. Pre-registration is required for the call. A webcast with replay will also be available on the company's website. Autolus, a biopharmaceutical company, specializes in next-generation T-cell therapies for cancer...
03-16 20:10
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics plc will participate in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2028, in Boston, MA, and the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami, FL. CEO Dr. Christian Itin will present at the Boston conference. A live webcast and replay will be available on the company's website. Autolus develop advanced T cell therapies for cancer and autoimmune diseases, ...
02-24 12:00
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
HC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $9.
02-17 19:37
Autolus Therapeutics' Subsidiary Signs Agreement With AGC Biologics To Manufacture, Supply Lentiviral Vector
https://www.sec.gov/ix?doc=/Archives/edgar/data/1730463/000173046326000019/autl-20260121.htm
01-27 05:14
